Research onlyWeight lossSubcutaneousEvidence 2/5

Adipotide

Also known as: FTPP, prohibitin-targeting peptide

Adipotide is a chimeric peptidomimetic whose CKGGRAKDC homing motif binds prohibitin on white-fat blood-vessel endothelium, where its fused D(KLAKLAK)2 segment disrupts mitochondrial membranes to trigger endothelial apoptosis and regression of the fat tissue's blood supply.

Read guide Buy / compare source

Adipotide

Drug class: Pro-apoptotic peptidomimetic (vascular-targeting antiobesity agent)
Primary targets: Prohibitin (white adipose tissue endothelium), Annexin A2-prohibitin receptor complex, Mitochondrial membrane (via D(KLAKLAK)2 motif)
Dose reference: Preclinical/Phase 1 reference only, NOT a recommendation: ~0.43 mg/kg/day subcutaneously for 28 days in obese monkeys; first-in-human Phase 1 started near 0.03 mg/kg/day SC. No approved human dose.
Half-life: Not well characterized in humans; dosed once daily by subcutaneous injection in animal and Phase 1 studies
Developer / origin: Kolonin, Pasqualini and Arap laboratories (MD Anderson / UT Health Science Center); clinical development via Ablaris Therapeutics / Arrowhead Pharmaceuticals
Reference year: 2011
Evidence score: 2/5 - Preclinical only; human program halted

Evidence 2/5

Preclinical only; human program halted

Adipotide showed dramatic targeted fat loss in obese monkeys and rodents via prohibitin-directed vascular apoptosis, but it has no validated human efficacy or safety; its first-in-human Phase 1 oncology trial was halted and development was discontinued, primarily over renal toxicity.

Mostly animal, ex vivo, cell, or indirect evidence.

Evidence basis

28-day study in obese rhesus monkeys (Science Translational Medicine, 2011): ~7-15% body weight loss and ~39% total body fat reduction at 0.43 mg/kg/day SC
Original concept and target validation in rodents (Nature Medicine, 2004): prohibitin identified as white-fat vascular marker
Annexin A2-prohibitin receptor system confirmed in adipose vasculature (JCI Insight, 2016)
First-in-human Phase 1 trial NCT01262664 (MD Anderson) in metastatic prostate cancer with obesity; program halted with nephrotoxicity as central concern
Dose-dependent, reversible renal changes observed even in primate studies

Key references

Science Translational MedicineA peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Nature MedicineReversal of obesity by targeted ablation of adipose tissue
JCI InsightProhibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue
ClinicalTrials.govPhase I Evaluation of Prohibitin Targeting Peptide 1 in Metastatic Prostate Cancer and Obesity (NCT01262664)

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.